Literature DB >> 12691777

Nutritional management of anorexic patients with and without fluoxetine: 1-year follow-up.

Giovanni M Ruggiero1, Massimo C Mauri, Anna C Omboni, Lucia S Volonteri, Savina Dipasquale, Lara Malvini, Gabriella Redaelli, Lucia Pasqualinotto, Francesco Cavagnini.   

Abstract

This study evaluated the efficacy of nutritional management with and without fluoxetine (FLX) in anorexia nervosa diagnosed according to Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) criteria. Twenty-one patients, with a mean body mass index (BMI) of 15.21+/-2.33 kg/m(2), were treated with nutritional management and FLX at a mean dosage of 30.00+/-9.35 mg (pharmacological group); seventy-four patients, with a mean BMI of 14.24+/-2.16 kg/m(2), were treated only with nutritional management (nutritional group). Clinical evaluation was carried out under single-blind conditions at basal time and after 3, 6, and 12 months by a structured clinical interview, the Eating Disorder Interview based on Longitudinal Interval Follow-Up Evaluation (EDI-LIFE) and using a self-reported questionnaire, the Eating Disorder Inventory (EDI). BMI significantly increased in both the two treatment groups. In addition, the increase shown by the pharmacological group appeared near the beginning of treatment (i.e., at T1) and it was significantly higher than the increase shown by the nutritional group. Physical exercise showed a significant decrease in the pharmacological treatment group. On the other hand, fear of fatness and the scores of the subscales of the EDI significantly decreased in the nutritional treatment group. In terms of weight, the pharmacological group presented the higher amount of therapeutic success.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12691777     DOI: 10.1016/S0278-5846(03)00029-0

Source DB:  PubMed          Journal:  Prog Neuropsychopharmacol Biol Psychiatry        ISSN: 0278-5846            Impact factor:   5.067


  4 in total

Review 1.  The Role of Psychotropic Medications in the Management of Anorexia Nervosa: Rationale, Evidence and Future Prospects.

Authors:  Guido K W Frank; Megan E Shott
Journal:  CNS Drugs       Date:  2016-05       Impact factor: 5.749

2.  Psychotropic medication use in anorexia nervosa between 1997 and 2009.

Authors:  Pouneh K Fazeli; Genevieve L Calder; Karen K Miller; Madhusmita Misra; Elizabeth A Lawson; Erinne Meenaghan; Hang Lee; David Herzog; Anne Klibanski
Journal:  Int J Eat Disord       Date:  2012-06-26       Impact factor: 4.861

Review 3.  The psychopharmacotherapy of anorexia nervosa: clinical, neuroendocrine and metabolic aspects.

Authors:  G Abbate Daga; L Gianotti; V Mondelli; R Quartesan; S Fassino
Journal:  J Endocrinol Invest       Date:  2004-11       Impact factor: 4.256

4.  Beyond Refeeding: The Effect of Including a Dietitian in Eating Disorder Treatment. A Systematic Review.

Authors:  Yive Yang; Janet Conti; Caitlin M McMaster; Phillipa Hay
Journal:  Nutrients       Date:  2021-12-15       Impact factor: 5.717

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.